No real thoughts. This isn't a current revenue story. Anything over $65MM would be ok, although it really takes a couple more $MM to make people happy (I'd like $80MM, which is just barely possible) We won't see any effect of the PML case this quarter; on the other hand, we won't see any effect of the evidence that early commencement of Jakafi has long-lasting benefits. Management MUST deliver something against the promise of big news coming--they'd be better off to annoy FDA by releasing raw data on '110 than to infuriate analysts by saying "trust us." Or they could say (if it's true) that the median survival of all patients combined in the pancreatic CA study was x% longer than the predicted median, so they were very hopeful etc. They have to say something. Still a discovery and development shop--Pinocchio needs 3 marketed products to be a REAL boy...errr...drug company.